Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-powered drug discovery company, has integrated advanced AI chat functionality based on recent advances in large language models into its PandaOmics platform. The new feature, "ChatPandaGPT," enables researchers to have natural language conversations with the platform and efficiently navigate and analyze large datasets, facilitating the discovery of potential therapeutic targets and biomarkers in a more efficient manner.

from Breaking World Pharma News https://ift.tt/khTqEMP